QURE241220P23000
- 0.00
- 0.000.00%
uniQure NV Newsroom
Uniqure Insider Sold Shares Worth $1,503,000, According to a Recent SEC Filing
UniQure Is Maintained at Neutral by Goldman Sachs
Express News | Guggenheim Reiterates Buy on UniQureto Buy
Goldman Sachs Maintains UniQure NV(QURE.US) With Hold Rating, Raises Target Price to $20
UniQure Is Maintained at Outperform by RBC Capital
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $8.69 to $58
Express News | Uniqure NV : Leerink Partners Raises Target Price to $44 From $26
Sector Update: Health Care Stocks Decline Late Afternoon
UniQure Gets Rating Upgrade From Wells Fargo After Agreement With FDA -- Shares Continue Rally
Top Midday Gainers
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings
UniQure Price Target Raised to $52.00/Share From $20.00 by Raymond James
UniQure Raised to Strong Buy From Outperform by Raymond James
UniQure Stock Rockets 90% on FDA Update for AMT-130
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday
US stock market movements | uniQure NV (QURE.US) soared over 121% after reaching an agreement with the FDA, triggering a trading halt at one point.
On Tuesday, uniQure NV (QURE.US) opened soaring over 121%, triggering a halt at one point, reported at $14.87.
Express News | Cantor Fitzgerald Maintains Overweight on UniQure, Raises Price Target to $58
UniQure Analyst Ratings
Dow Falls 150 Points; Oracle Posts Downbeat Results